Celcuity Inc. (CELC)
| Market Cap | 3.22B+33.7% |
| Revenue (ttm) | n/a |
| Net Income | -226.48M |
| EPS | -4.31 |
| Shares Out | 48.93M |
| PE Ratio | n/a |
| Forward PE | -822.25 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 2,654,256 |
| Open | 70.52 |
| Previous Close | 71.25 |
| Day's Range | 64.16 - 73.50 |
| 52-Week Range | 45.03 - 151.02 |
| Beta | 0.11 |
| Analysts | Strong Buy |
| Price Target | 156.91(+138.54%) |
| Earnings Date | Nov 11, 2026 |
Insiders filed in the last 90 days, but none of those trades qualified for scoring — round-trip buys and filings whose price is far off the market are excluded.
About CELC
Celcuity Inc., a clinical-stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's lead drug candidate includes Gedatolisib, which selectively targets various Class I isoforms of phosphatidylinositol-3-kinase (PI3K) and the two mechanistic targets of rapamycin (mTOR) sub-complexes, mTORC1 and mTORC2 to treat patients with hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-) or HR+/HER2-, advanced or metastatic breast cancer (ABC), and patients with metastatic castration resistant prostate cancer (mCRPC). The company had a license agreement with Pfizer Inc. for the development and commercialization rights to Gedatolisib. Celcuity Inc. was incorporated in 2011 and is based in Minneapolis, Minnesota.
What Are Insiders Doing?
View the trades behind this meter — each links to its SEC Form 4 →
Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.
$CELC stock is featured in our Insider Score Rankings, and Insider Trades datasets.
→ All Stock ListsRecently reported changes in CELC holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by CELC's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
CELC Estimated quarterly lobbying spending
Source: U.S. Senate LDA
U.S. Patents
New CELC patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to CELC from public contracts
Source: USAspending.gov
CELC Insider Score
Our composite score: insider buying, sector, volume, tone & dilution
Bull Case vs Bear Case
AI-generated from CELC’s recent data — informational, not investment advice
Insider Score
Our 0–100 Insider Score and the signals behind it.
The live Insider Score and its full factor breakdown are included with Insider Access.
Unlock Insider Score